Eli Lilly (NYSE:LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company ...

Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Lilly has also submitted marketing applications for Omvoh in Crohn's disease around the globe, including in the European Union and Japan. Additional global regulatory submissions are planned.

Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Omvoh ...

Eli Lilly and Co.’s approval for Omvoh to treat moderate to severe Crohn’s disease in adults marks the Indianapolis company’s growing presence in the treatment of inflammatory bowel disease ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.

Lilly's Omvoh receives US FDA approval to treat Crohn's disease in adults Indianapolis Friday, January 17, 2025, 12:00 Hrs [IST] Eli Lilly and Company announced that the US Food and Drug ...

About Omvoh ® Omvoh ® (mirikizumab) is an interleukin-23p19 antagonist indicated for the treatment of moderately to severely active ulcerative colitis in adults.

Lilly has also submitted marketing applications for Omvoh in Crohn's disease around the globe, including in the European Union and Japan. Additional global regulatory submissions are planned.